ProPhase Labs Inc is a drug manufacturers-specialty & generic business based in the US. ProPhase Labs shares (PRPH) are listed on the NASDAQ and all prices are listed in US Dollars. ProPhase Labs employs 95 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $7.30 |
|---|---|
| 52-week range | $4.20 - $11.81 |
| 50-day moving average | $6.76 |
| 200-day moving average | $6.01 |
| Wall St. target price | $9.67 |
| PE ratio | N/A |
| Dividend yield | N/A (13.16%) |
| Earnings per share (TTM) | $-0.37 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.3 from 2022-01-14
| 1 week (2022-01-11) | -4.58% |
|---|---|
| 1 month (2021-12-14) | N/A |
| 3 months (2021-10-18) | 28.07% |
| 6 months (2021-07-17) | 21.06% |
| 1 year (2021-01-15) | -54.38% |
|---|---|
| 2 years (2020-01-17) | 298.91% |
| 3 years (2019-01-18) | 142.93% |
| 5 years (2017-01-18) | 263.18% |
| Revenue TTM | $39 million |
|---|---|
| Gross profit TTM | $4.6 million |
| Return on assets TTM | -8.55% |
| Return on equity TTM | -18.07% |
| Profit margin | -13.56% |
| Book value | $3.08 |
| Market capitalisation | $113 million |
TTM: trailing 12 months
We're not expecting ProPhase Labs to pay a dividend over the next 12 months.
ProPhase Labs's shares were split on a 2:1 basis on 22 January 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ProPhase Labs shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ProPhase Labs shares which in turn could have impacted ProPhase Labs's share price.
Over the last 12 months, ProPhase Labs's shares have ranged in value from as little as $4.2023 up to $11.8065. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProPhase Labs's is -0.1004. This would suggest that ProPhase Labs's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, ProPhase Labs has bucked the trend.
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc.
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.